Avotaciclib (trihydrochloride)

Avotaciclib (BEY1107) trihydrochloride is an orally active cyclin-dependent kinase 1 (CDK1) inhibitor. Avotaciclib trihydrochloride can inhibit the proliferation and induce apoptosis of tumor cells. Avotaciclib trihydrochloride can be used in the research of cancer such as pancreatic cancer and lung cancer[1][2].

Product Specifications

CAS Number

[1983984-01-5]

Product Name Alternative

BEY1107 (trihydrochloride)

UNSPSC

12352005

Target

Apoptosis; CDK

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/avotaciclib-trihydrochloride.html

Purity

99.60

Solubility

DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

OC1=CC=C(C2=NC(N)=NC=C2)N=C1C3=NC(N)=NC=C3.[H]Cl.[H]Cl.[H]Cl

Molecular Formula

C13H14Cl3N7O

Molecular Weight

390.66

References & Citations

[1]Seufferlein T, et, al. Phase I Trials in Pancreatic Cancer. Translational Pancreatic Cancer Research pp 219-232. |[2]Zhang L, et al. Suppression of cyclin-dependent kinase 1 synergizes with checkpoint kinase 2 inhibitor to promote death of non-small cell lung cancer cells with radiotherapeutic resistance. Journal of Radiation Research and Applied Sciences, 2024, 17 (2) : 100900.